Olatec Therapeutics

NY - New YorkBiotechnology5 H-1B visas (FY2023)

Focus: Olatec Therapeutics is a New York-based biotech company focused on developing treatments for inflammatory diseases, particularly in immunology. The company is in early-stage development with a diversified pipeline targeting multiple indications.

Immunology

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PRIVATE

Open Jobs

About Olatec Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Olatec Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OLT1177 Capsules

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02134964Phase 1 Safety and PK Study of OLT1177 Capsules

Phase 1

Help build intelligence for Olatec Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a diversified pipeline with 11 active programs spanning Phase 1–3, offering exposure to multiple therapeutic areas within immunology and inflammation
Early-stage biotech environment allows direct impact on drug development strategy and potential equity upside before public markets
H1B sponsorship demonstrated (5 approvals in 2023), indicating willingness to recruit specialized talent globally

Watch Out For

Pre-revenue private company with no disclosed funding or cash position creates uncertainty around runway and long-term stability
Zero active job openings and no hiring data suggest the company may be in a hold phase or severely resource-constrained
Early pipeline maturity (no Phase 3 programs close to completion) means regulatory milestones and revenue are years away

Generated by Claude from Olatec Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

dapansutrile capsules

Systolic Heart Failure

Phase 1

Clinical Trials (1)

NCT03534297Study of Dapansutrile Capsules in Heart Failure

Phase 1

OLT1177 Gel

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT01636141Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

Phase 1